Gland Pharma Ltd, established in 1978, is a major player in the manufacturing of injectable formulations, focusing on generic injectables. The company has a strong presence in the US market and over 60 countries, with eight manufacturing facilities in India, including four finished formulation plants and three API facilities. It operates primarily on a B2B model and is distinguished by its robust regulatory compliance and expertise in complex injectables development and manufacturing. Gland Pharma's capabilities are enhanced by its vertically integrated structure, which includes in-house R&D, cost control, and quality assurance.
The company has expanded its portfolio to include contract development, technology transfer, and manufacturing across various delivery systems. As of March 2022, Gland Pharma, along with partners, had 284 ANDA filings in the US, with 234 approvals. In 2023, the company made strategic acquisitions, including Phixen SAS and entities within Cenexi, to further its global reach, while also launching new products like 'Dexrazoxane' in China.
